Antiverse Raises $9.3M Series A Led by Soulmates Ventures

Why It Matters

The capital accelerates AI‑powered discovery for previously undruggable targets, potentially reshaping biotech pipelines and opening new therapeutic avenues for diseases like cystic fibrosis.

Key Takeaways

• $9.3M Series A brings total funding above $20M.
• AI platform targets hard-to-drug GPCRs and ion channels.
• Collaboration with Cystic Fibrosis Foundation focuses on extracellular CFTR.
• Platform claims antibody design cycle under four months.
• Goal: advance internal candidates to preclinical stage by 2027.

Pulse Analysis

Antiverse’s latest financing underscores a broader shift toward artificial intelligence in biologics R&D. By marrying generative models with programmable cell‑line engineering, the company shortens the traditionally lengthy antibody discovery timeline. Investors such as Soulmates Ventures see the platform’s ability to tackle GPCRs, ion channels, and other elusive epitopes as a differentiator that could unlock sizable market segments previously considered intractable.

The partnership with the Cystic Fibrosis Foundation highlights a strategic focus on high‑need, hard‑to‑drug indications. Extracellular CFTR has resisted conventional antibody approaches, limiting therapeutic progress for cystic fibrosis. Antiverse’s AI‑driven modelling aims to generate epitope‑specific candidates that can be screened in native cell models, potentially accelerating translational research and offering a new modality for a disease affecting millions worldwide.

Beyond the CF collaboration, Antiverse is positioning itself as a versatile partner for top‑tier pharma and biotech firms. With offices in Cardiff, Boston, and Prague, the company leverages a global talent pool to scale its platform and pipeline. The goal of moving internal candidates into later‑stage preclinical work by 2027 signals confidence in its technology’s speed and efficacy, setting a competitive benchmark for the emerging AI‑bio frontier.

Deal Summary

Antiverse, an AI-driven antibody design company, announced a $9.3 million Series A round led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital and i&i Biotech Fund. The funding brings total capital to over $20 million and will be used to scale its generative antibody platform and advance its pipeline.